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ABSTRACT Exonic splicing enhancers (ESEs) activate pre-
mRNA splicing by promoting the use of the flanking splice sites.
They are recognized by members of the serineyarginine-rich
(SR) family of proteins, such as splicing factor 2yalternative
splicing factor (SF2yASF), which recruit basal splicing factors to
form the initial complexes during spliceosome assembly. The in
vitro splicing kinetics of an ESE-dependent IgM pre-mRNA
suggested that an SF2yASF-specific ESE has additional func-
tions later in the splicing reaction, after the completion of the
first catalytic step. A bimolecular exon ligation assay, which
physically uncouples the first and second catalytic steps of
splicing in a trans-splicing reaction, was adapted to test the
function of the ESE after the first step. A 3* exon containing the
SF2yASF-specific ESE underwent bimolecular exon ligation,
whereas 3* exons without the ESE or with control sequences did
not. The ESE-dependent trans-splicing reaction occurred after
inactivation of U1 or U2 small nuclear ribonucleoprotein parti-
cles, compatible with a functional assay for events after the first
step of splicing. The ESE-dependent step appears to take place
before the ATP-independent part of the second catalytic
step. Bimolecular exon ligation also occurred in an S100
cytosolic extract, requiring both the SF2yASF-dependent ESE
and complementation with SF2yASF. These data suggest that
some ESEs can act late in the splicing reaction, together with
appropriate SR proteins, to enhance the second catalytic step
of splicing.
The removal of introns from pre-mRNA involves two transes-
terification steps. Many intronic and exonic sequence elements
function as splicing signals in constitutive and regulated splicing.
One class of element, exonic splicing enhancers (ESEs), stimu-
lates processing of upstream introns. Members of the seriney
arginine-rich (SR) protein family have been directly implicated in
the mechanisms of ESE function (1). SR proteins are also
essential splicing factors required for spliceosome assembly and
progression through the first transesterification step. ESEs ap-
pear to function as specific binding sites for SR proteins, which
then recruit other factors to the splice sites, promoting assembly
of the earliest prespliceosomal complexes (2). However, some SR
proteins remain associated with the mRNA throughout the
splicing reaction and probably during mRNA transport through
the nuclear pores (3–7). Thus, ESEs and SR proteins may have
additional functions beyond the early stages of splicing.
One of the best characterized ESE-containing pre-mRNAs
consists of the last intron and last two membrane-isoform exons
(M1 and M2) of the Ig m heavy chain (IgM) gene (8). An ESE
located in the M2 exon promotes early spliceosome assembly,
leading up to the first catalytic step (8). This ESE can be replaced
by other enhancer sequences to activate splicing (9, 10). However,
an effect of this or other ESEs on the second step of splicing had
not been reported. While studying splicing of this substrate, we
observed an unexpected splicing pattern with kinetics suggestive
of ESE function in the second step of splicing. We exploited a
bimolecular exon ligation reaction that uncouples the two trans-
esterification steps of splicing (11) to further explore a require-
ment for ESE action late in the splicing reaction, after the
completion of the first catalytic step.
MATERIALS AND METHODS
RNA Substrates. IgM transcription templates were made by
PCR using primers P and A (10), with pmMD (8) or splicing factor
2yalternative splicing factor (SF2yASF)-winner clone B1 (10) as
DNA templates. The adenovirus major late (AdML) transcrip-
tion template for cis-splicing was the BamHI-linearized plasmid
pAdML PAR (17). For the 59 fragment AdML DAG transcrip-
tion template, PCR was performed with a T7 RNA polymerase
promoter primer and primer DAG-A (AGAGAGAGAG-
GAAAAAAAAGGGA), using pAdML DAG as a template. 39
M2 exons were made by PCR with primer SP6-PPT-IgM-S
(ATTTAGGTGACACTATAGCTGTCTCTGTCACCTGCA-
GGTGAAATGACTCTCAGCAT) or SP6-TGCAG-IgM-S
(ATTTAGGTGACACTATAGTGCAGGTGAAATGACTC-
TCAGCAT) and primer A. The template for 39 exon PCR was
SF2yASF winner clone B1 (10) or an enhancer-deleted construct
initially made with primer RD (GTGAAATGACTCTCAG-
CATTCTAGTAAACTTATTCTTACGT) and primer A. The
39 fragment M2-D differs from the downstream exon of mMD by
including 10 nucleotides (neutral in cis-splicing assays) immedi-
ately upstream of the wild-type enhancer (8). In vitro-transcribed
RNA was labeled with [32P]GTP and then gel-purified and
quantitated, or labeled with [3H]GTP and then DNase-treated
and quantitated. The 39 M2 exons with deletions of the exonic
splicing silencer element (12) (M2-SF2W-dsil and D-dsil) were
made by running off transcripts at a BfaI site.
Splicing Reactions. Totals of 20 fmol of 59 RNA and 100 fmol
of 39 RNA were used in 25-ml reactions containing 32% nuclear
extract or S100 cytosolic extract and 3.2 mM MgCl2 (13). Totals
of 5, 10, or 20 pmol of purified Escherichia coli-expressed
SF2yASF (14), or baculovirus-expressed SC35 or SRp55, were
used in S100 complementation reactions. Anti-U1 (nucleotides
2–11) and anti-U2 (nucleotides 1–15) oligonucleotides were used
at 16 mM for RNase H experiments (15). ATP was depleted by
addition of glucose to 5 mM and hexokinase to 50 unitsyml for
15 min at 30°C (16). Splicing reaction products were separated on
denaturing 5.5%, 10%, or 12% polyacrylamide gels. The trans-
spliced mRNA product was excised from the gel, eluted, reverse
transcribed with primer A by using Superscript II (Life Technol-
ogies), and PCR-amplified with primer Ad5p (CGTTCGTCCT-
CACTCTCTT) and primer A by using Pfu DNA polymerase
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(Stratagene). The product was cloned into pCR-blunt (Invitro-
gen) and sequenced.
RESULTS
Splicing Kinetics of an ESE-Dependent IgM pre-mRNA Sug-
gest an Additional Enhancement of the Second Catalytic Step.
Splicing was compared between an IgM substrate with an in
vitro-selected SF2yASF-specific ESE (10) (IgM-SF2W) in place
of the wild-type M2 exon enhancer, and a substrate in which the
wild-type ESE had been removed (mMD) (8). Both IgM-SF2W
and mMD gave first-step intermediates in nuclear extract (be-
tween 0.5 and 1 hr; lanes 4 and 10), but only IgM-SF2W RNA
gave second-step products (Fig. 1). The IgM pre-mRNA is
strongly (but not completely) dependent on enhancer sequences
for the first catalytic step of splicing, and this is reflected in Fig.
1, as there was no increased accumulation of splicing intermedi-
ates with the mMD substrate compared with IgM-SF2W. Never-
theless, the kinetics of appearance of the first-step intermediates
and second-step products suggested an additional effect of the
ESE.
Bimolecular Exon Ligation of the M2 Exon Requires an
Enhancer. To directly test the mechanisms of ESE action on the
second step of splicing, we used a trans-splicing assay developed
by Anderson and Moore (ref. 11, and Fig. 2A). A 59 RNA
substrate containing an upstream exon and an intron with a
strong branch site and polypyrimidine tract can efficiently un-
dergo the first step of splicing. Then, subsequent excess addition
of a 39 RNA containing a 39 splice site and a downstream exon
allows the second step to occur, generating a trans-spliced mRNA
product. This physical separation of the first and second catalytic
steps makes it possible to test whether an ESE can be recognized
and participate in splicing after the completion of the first step.
As previously reported, a radiolabeled 59 RNA substrate [AdML
DAG, containing the AdML first leader exon and first intron,
including the branch site and an improved 39 polypyrimidine tract
(17)] could undergo the first step of splicing in HeLa nuclear
extract (Fig. 2B, lanes 4–6). As a 39 RNA substrate, we used the
M2 exon with a 20-nt in vitro-selected ESE, which was shown to
be a strong SF2yASF-specific enhancer by both splicing and
FIG. 2. ESE dependence of bimolecular exon ligation. (A) A scheme
of the trans-splicing assay is shown, with the 59 leader exon denoted by the
boxed L1 and the intron by a line ending with ‘‘cu’’ (17). After incubation,
to allow the first step of splicing to occur, IgM M2 exon (with a 39 splice
site) was added as a 39 substrate. (B) AdML DAG RNA was 32P-labeled
and incubated in nuclear extract for the times shown (lanes 4–6).
3H-labeled 39 exons were added for the second and third hours of the
reactions (lanes 7–10). The trans-spliced mRNA (TS) is shown by a black
arrow. The expected position of trans-splicing with M2-D is marked by a
dashed open arrow. Control splicing in cis between AdML PAR exons L1
and L2 is shown in lanes 1–3. (C) In a reciprocal labeling experiment, the
39 exons were 32P-labeled, and the 59 fragment was made with [3H]GTP.
Controls with 32P-labeled AdML DAG pre-mRNA are shown in lanes 1
and 2. Other controls omitting the 3H-labeled 59 RNA are shown in lanes
3 and 6. A longer exposure of the trans-spliced products is shown. In B
(and in subsequent figures), the asterisk indicates an artifactual band
characteristic of the AdML PAR substrate (11, 17); the triangle indicates
an artifactual product that appears to derive from the AdML DAG lariat
intermediate or from use of an alternative branch site.
FIG. 1. In vitro splicing kinetics of IgM pre-mRNA. A time course
of cis-splicing of IgM pre-mRNAs with (IgM-SF2W) or without
(mMD) an SF2yASF-specific ESE is shown. The positions of the
pre-mRNA, 59 exon M1 and lariat-exon M2 intermediates, and splicing
products are shown by diagrams on the right. A dashed arrow shows
the expected position of the mMD-spliced product. Lane 1, pBR322y
MspI size markers; lanes 7 and 13, control reactions lacking ATP.
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binding assays (10). 3H-labeled 39 RNA substrates with (M2-
SF2W) or without (M2-D) the ESE, were added to the reactions
in 5-fold molar excess. A trans-spliced mRNA was reproducibly
seen when M2-SF2W was added (Fig. 2B, lanes 7 and 8), but not
with M2-D (lanes 9 and 10). In a reciprocal labeling experiment
(11), again, a trans-spliced mRNA product was reproducibly seen
with M2-SF2W (Fig. 2C, lanes 4 and 5) and not with M2-D (lanes
7 and 8). The lack of trans-splicing with M2-D was not an artifact
of deletion and exon shortening, as four additional variants of the
M2 exon, containing control sequences (C3, C4, C6, and C7 in ref.
10) instead of an SF2yASF-ESE, did not show trans-splicing in
nuclear extract (data not shown). The M2-SF2W and M2-D exons
were equally stable during incubation for up to 2 hr in the splicing
reaction (Fig. 2C, lanes 4 and 5 compared with lanes 7 and 8). The
trans-spliced band was verified as a correctly spliced mRNA by
sequencing.
SF2yASF Is Required for Enhancer-Dependent Bimolecular
Exon Ligation. To test the mechanism of action of the SF2W
enhancer, we performed trans-splicing in an S100 extract comple-
mentation assay (18). As a cis-splicing control, the full-length
AdML PAR RNA (17) spliced efficiently in S100 extract com-
plemented with recombinant SF2yASF, but not in S100 alone
(Fig. 3A, lanes 3 and 4). This result suggests that either AdML
pre-mRNA splicing is activated by a general action of SF2yASF
(19), or there are one or more SF2yASF-dependent enhancers
within the AdML substrate, as described for other constitutive
exons (20, 21). To carry out bimolecular exon ligation assays, the
59 RNA AdML DAG substrate was first shown to undergo the
first splicing step in S100 extract complemented with SF2yASF
(Fig. 3B, lane 3). It did so only slightly less efficiently than in
nuclear extract (lane 1), whereas the reaction was extremely
inefficient in S100 extract alone (lane 2). A trans-spliced mRNA
product was seen when the M2-SF2W exon was added to nuclear
extract (lane 4) and, faintly, in S100 complemented with SF2y
ASF (lane 6), but not when M2-D exon was added (lanes 7–9).
Reciprocal labeling was used to improve the electrophoretic
separation and detection of the trans-spliced product in S100
complemented with SF2yASF (Fig. 3C, lane 1) and to confirm
the absence of a product with the M2-D exon (lane 3). The
trans-spliced product accumulated to lower levels in S100 extract
complemented with SF2yASF, compared with the nuclear ex-
tract, in contrast to the cis-splicing substrate, which was spliced
with comparable efficiency in both extracts (Fig. 3A); however,
the amount of intermediates in the trans-splicing reaction was
also reduced. Four other in vitro-selected SF2yASF-dependent
ESEs (B2-B5 in ref. 10) were also tested, and all enhanced
trans-splicing in S100 extract complemented with SF2yASF (data
not shown).
The SF2yASF-ESE Functions in the Context of a Downstream
Exonic Splicing Silencer Element. A silencer element in the IgM
M2 exon was recently identified in cis-splicing experiments (12).
We tested the function of this silencer, vis-a`-vis an enhancer, in
bimolecular exon ligation. Removal of the silencer from the
M2-SF2W substrate increased the ratio of trans-spliced mRNA to
unspliced 39 exon (Fig. 4, lanes 1 and 2). With the M2-D substrate,
which lacks the ESE, trans-splicing was nearly undetectable (lanes
3 and 3D). However, removal of the silencer in addition to the
ESE resulted in a substantial increase in trans-splicing (lanes 4
and 4D). Thus, the silencer can antagonize an enhancer in both
cis-splicing (12) and trans-splicing assays.
SF2yASF Specificity of Bimolecular Exon Ligation Enhance-
ment. To test the specificity of SF2yASF function in trans-splicing
via the SF2W ESE, we performed the reactions in S100 extract
complemented with one of three human recombinant SR pro-
teins. SF2yASF and SC35 generated first-step splicing interme-
diates at similar levels, whereas SRp55 did so less efficiently (Fig.
5A, lanes 4–6). However, trans-spliced mRNA was reproducibly
generated more efficiently in reactions containing SF2yASF than
in those with SC35 or SRp55 (Fig. 5B, lanes 3–5). In comparisons
across a range of SR protein concentrations, the ratio of trans-
spliced product to unspliced 39 exon was 11-fold higher (SE 6 3.8;
n 5 7) in SF2yASF than in SC35 complementation reactions.
The Trans-Spliced Products Are Generated from Accumu-
lated First-Step Intermediates. Although different 39 exons have
no effect on the efficiency with which the 59 substrate undergoes
the first step (11), it remained possible that the M2-SF2W exon
underwent trans-splicing by promoting spliceosome assembly on
unprocessed AdML DAG pre-mRNA, rather than by a direct use
of the first-step upstream exon and intron lariat intermediates
already assembled into a spliceosome. To rule out a first-step
effect of the ESE in the free 39 exon, processing of any pre-mRNA
remaining prior to addition of the 39 exon substrates was blocked
by inactivation of U1 or U2 small nuclear RNAs via oligonucle-
otide-directed RNase H cleavage (15). We allowed first-step
AdML DAG intermediates to accumulate, then inactivated U1 or
U2, before finally adding the downstream M2-SF2W exon. Trans-
splicing products were still detected (Fig. 6, lanes 2 and 3). Parallel
control reactions were initially incubated without RNA for the
first hour, then treated with or without oligonucleotides, before
addition of AdML DAG for the final hour. Inactivation of U1 or
FIG. 3. Trans-splicing requirement for an ESE and SF2yASF. (A) Control AdML PAR pre-mRNA cis-splicing was carried out in nuclear extract
(NE) or in S100 extract complemented with SF2yASF. Lane 1, size markers. (B) Trans-splicing reactions were performed in nuclear extract or
in S100 extract with or without SF2yASF. 32P-labeled AdML DAG was incubated for 1 hr, and then excess 3H-labeled M2-SF2W, or M2-D, or water
was added for the second hour. Trans-spliced mRNA (TS, lanes 4 and 6) is marked by a black arrow, and the expected position of the M2-D mRNA
is marked with a dashed open arrow. (C) A reciprocal labeling experiment is shown. The top part of the autoradiogram is a longer exposure.
Biochemistry: Chew et al. Proc. Natl. Acad. Sci. USA 96 (1999) 10657
U2 effectively inhibited the first step of splicing during the final
hour of incubation (lanes 5 and 6). Note that under these
conditions, the efficiency of the first step is already reduced
because of the preincubation itself (lane 4). The amount of
trans-spliced product was slightly reduced in the anti-U2-treated
reactions (lane 3), possibly because some of the anti-U2 oligo-
nucleotide was able to target U2 small nuclear ribonucleoprotein
(snRNP) already assembled into spliceosomes. U2 small nuclear
RNA is involved in the second catalytic step of splicing (22).
Bimolecular Exon Ligation Is ATP-Dependent. The second
step of splicing includes the assembly onto the spliceosome of four
protein factors dispensable for the earlier stages of the reaction
(Prp16, Prp17, Slu7, and Prp18) (22). In Saccharomyces cerevisiae,
the order of action of these factors has been established with
respect to the ATP dependence of the second step. The identi-
fication of functional human homologues shows the mechanistic
conservation of the second-step processes (23, 24). To charac-
FIG. 4. Interaction between enhancer and silencer elements in trans-
splicing. (A) 3H-labeled AdML DAG pre-mRNA was incubated for 1 hr
in nuclear extract. Then, the indicated 32P-labeled 39 M2 exons with or
without an ESE or a silencer were added. The lower and upper brackets
on the right show the positions of the 39 exons and of the trans-spliced
mRNAs, respectively. A longer exposure of lanes 3 and 4 is shown (lanes
3D and 4D). (B) Schematic structure of the different 39 M2 exons. The
ESE is shaded gray, and the silencer segment (ESS) is shaded black. (C)
Relative trans-splicing efficiencies of the four 39 exons. The data from A
were quantitated by densitometry and normalized for loading and dif-
ferential labeling of the 39 exons. The efficiency of the SF2W 39 exon was
arbitrarily set at 1. FIG. 5. SR protein specificity of second-step trans-splicing en-
hancement. (A) 32P-labeled AdML DAG pre-mRNA was incubated
for 1 hr in S100 extract (with or without the indicated SR proteins), and
3H-labeled M2-SF2W 39 exon was added for the second hour. Trans-
spliced mRNA is shown by the black arrow. Lane 1: size markers. (B)
A reciprocal labeling experiment is shown. The top part of the
autoradiogram is a longer exposure. Lane 1, size markers.
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terize the energy requirement of ESE-dependent bimolecular
exon ligation, ATP was depleted from nuclear extract. A trans-
spliced mRNA product was no longer detected upon treatment
with glucose and hexokinase (Fig. 7, lane 4), but was detected in
control reactions (lanes 3, 5, and 6). Hexokinase alone slightly
reduced the level of the product (lane 6), either nonspecifically or
perhaps because of trace phosphate acceptors in the reaction.
DISCUSSION
Mammalian in vitro trans-splicing systems have provided insights
into the mechanisms of cis-splicing, in particular, showing the
enhancer dependence of one of the first-step trans-splicing sys-
tems (25, 26). In the second-step trans-splicing system, the first
step of splicing occurs in the absence of a downstream exon (11).
This reaction was adapted here to demonstrate the role of an
SF2yASF-specific ESE during, or just prior to, the second
catalytic step of splicing. Also examined were the requirements of
ESE-dependent bimolecular ligation for SF2yASF, ATP (both
required), and U1 or U2 snRNP (neither required).
A caveat is how closely the second step of the bimolecular exon
ligation assay relates to the second step of the natural cis-splicing
reaction. Although an ESE may function in the second step of
cis-splicing by an indirect mechanism involving changes in a
first-step component or configuration, none of the 39 exons used
affected the efficiency of the uncoupled first-step reaction (ref.
11, and this study). Moreover, the appropriate 39 splice site was
used in trans-splicing, and the spliced product was verified as
having the correct exon–exon junction. There is a close correla-
tion between the cis- and trans-splicing data in the context of the
IgM M2 exon. The SR protein specificity of the SF2yASF-ESE
was recapitulated in the trans-reaction as in the cis-reaction (ref.
10; and H.-X.L., S.L.C., M. Q. Zhang, and A.R.K., unpublished
work). Some cis- and trans-splicing was observed with the SF2y
ASF-ESE in S100 extract complemented with SC35, but both
reactions were less efficient than those with the cognate SR
protein, SF2yASF. Trans-splicing also recapitulated cis-splicing
in the context of the silencer element in the M2 exon. The ESE
may be required, in part, to overcome the silencer in both
reactions. Thus, the data are compatible with bimolecular exon
ligation representing a useful model for the second step of
splicing.
The 39 exons used in the original second-step bimolecular exon
ligation study (11) were derived from AdML exon L2 and chicken
cardiac troponin T (cTNT) exon 5. The latter exon contained an
ESE optimized by mutations (27). A reduction in trans-splicing
efficiency was observed when the AdML 39 L2 exon was replaced
by intronic sequences, compared with coding sequences from the
opposite viral DNA strand, suggesting that trans-splicing effi-
ciency may correlate with the presence of exonic sequences (11).
These data may reflect the presence of as yet unmapped ESEs in
the AdML L2 and antisense exons, which, like the IgM M2 ESE,
might act in the second step of splicing. An implication of the
present findings is that 39 exons able to undergo efficient bimo-
lecular exon ligation are expected to contain second-step ESEs.
Conversely, 39 exons incapable of this reaction probably lack such
ESEs, or may contain second-step silencers. An uncertainty is
whether the same ESE can always function to enhance both steps
of splicing, as seen with the SF2yASF-ESE. Detailed mutational
analysis and systematic evolution of ligands by exponential en-
richment experiments have shown that several, if not many,
splicing enhancers and silencers may lie in most exons (10, 20, 21,
28). It is possible that several functional classes of ESE may be
present in an exon, some perhaps being specific for a particular
step of splicing.
FIG. 6. Generation of trans-spliced products from accumulated
first-step intermediates. 32P-labeled AdML DAG RNA was processed
for 1 hr to give first-step intermediates, then incubated with buffer
(lane 1), anti-U1 (lane 2), or anti-U2 (lane 3) oligonucleotides for 15
min, and finally, excess tritiated M2-SF2W 39 exon RNA was added for
another hour. Control reactions were preincubated without RNA for
1 hr, treated with buffer or oligonucleotides, and AdML DAG RNA
was then added for a final hour of incubation.
FIG. 7. ATP dependence of ESE-stimulated bimolecular exon
ligation. Tritiated AdML DAG RNA was incubated for 1 hr (except in
lane 2), followed by glucose (glu) and hexokinase (hex; lane 3), or
control treatments (lanes 3, 5, and 6), with subsequent addition of
radiolabeled M2-SF2W 39 RNA. The trans-spliced product (TS) is
marked by an arrow. Lane 1, size markers.
Biochemistry: Chew et al. Proc. Natl. Acad. Sci. USA 96 (1999) 10659
We analyzed other ESE-containing exons to address the
generality of the present findings. Cis-splicing of HIV-Tat exons
2 and 3 and b-globin exons 1 and 2 is SF2yASF-dependent (21,
28). Tat exon 3 and b-globin exon 2 underwent trans-splicing in
an SF2yASF-dependent manner in S100 extract (data not
shown), suggesting that SF2yASF interacts with one or more
second-step ESEs in these exons. In contrast, we were unable to
recapitulate the well-characterized cis-splicing properties of other
exons by using the second-step trans-splicing assay. IgM C3 and
C4 exons are cis-spliced in an SC35-dependent manner in S100
extract (21). However, the IgM C4 39 exon did not yield detectable
trans-splicing in either nuclear extract or S100 extract comple-
mented with SC35. The SC35-dependent ESE may be relevant
only to the first step, or a second-step silencer may be present in
this exon, or this 39 exon may be intrinsically incompatible with
the heterologous AdML 59 substrate. We also analyzed mutants
of cTNT exon 5 that have a clear functional hierarchy in cis-
splicing enhancement (27). Unexpectedly, the different cTNT
substrates were equally efficient in trans-splicing in nuclear
extracts (data not shown). Again, this observation may indicate
the importance of sequence context for bimolecular exon ligation
(for example, the absence of a silencer sequence in cTNT exon 5),
or that second-step enhancers are present in this exon, but are
distinct from its well-characterized first-step enhancer.
Both the SF2yASF-specific ESE and SF2yASF are required
for bimolecular exon ligation of the IgM M2 exon. Since SF2y
ASF was added at the start of the reaction, it promotes the first
splicing step. A mechanistic difference between the general and
enhancer-dependent splicing functions of SF2yASF and other SR
proteins has been demonstrated (19). The formation of the
first-step intermediates in the bimolecular exon ligation system
may be because of a general function of SF2yASF, perhaps
mediated through protein–protein interactions, or perhaps via
binding to RNA sequences other than ESEs. However, the
efficient generation of first-step intermediates is not a sufficient
explanation for the ESE dependence of the trans-splicing reac-
tion. The efficiency of the first step was the same regardless of
which 39 exon was present, even exons lacking the SF2yASF-ESE
and therefore incapable of undergoing bimolecular exon ligation.
In addition, the formation of first-step intermediates was also
promoted by other SR proteins, but with much less trans-splicing
occurring. Thus, SF2yASF has an additional role in bimolecular
exon ligation, which is enhancer-dependent.
Although SF2yASF interacts directly with the SF2yASF-ESE
(10), it is not known whether this binding is relevant to the
second-step effect. It is possible that an indirect mechanism is
involved, e.g., involving protein–protein interactions. After the
first transesterification step, many changes occur within the
spliceosome (22). SR proteins act at later stages of spliceosome
assembly, but still before the first transesterification step, by
recruiting the U2 snRNP and U4yU5zU6 tri-snRNP (29, 30).
SF2yASF may similarly function to enhance the second step of
splicing by remodeling of the spliceosome. However, purified SR
proteins have also been reported to bring exons into proximity
without the need for snRNPs or other factors (31). They may have
a similar exon-bridging function in trans-splicing and during the
second catalytic step of cis-splicing. In this scenario, SF2yASF
may bring the 39 ESE-containing exon into the proximity of the
first-step intermediates, making an engagement with the spliceo-
some a more likely event. Alternatively, SF2yASF and the ESE
may serve to stabilize exon–exon interactions mediated by other
components. These mechanisms may or may not involve a specific
interaction of SF2yASF with the second-step catalytic machinery.
Another possibility is that SF2yASF and the SF2yASF-ESE
promote the second-step reaction by recruiting one or more
second-step factors.
The ATP dependence of the bimolecular exon ligation reaction
helps to order the ESE-dependent trans-splicing reaction to the
initial part of the second step. It suggests that the ESE-containing
exon enters the splicing reaction prior to the involvement of
hPrp18 and hslu7 (whose yeast counterparts participate in the
ATP-independent part of the second step). Any direct action of
SF2yASF and the SF2yASF-ESE may involve enhancement of
the recruitment of hPrp16 or hPrp17.
Here the bimolecular exon ligation reaction was used as a tool
to demonstrate an effect that is presumably relevant to cis-
splicing. If this assumption is correct, the late action of ESEs and
SR proteins may serve a proofreading role contributing to the
accuracy of cis-splicing by ensuring that the correct order of exons
in constitutively or alternatively spliced multiexon pre-mRNAs is
maintained throughout processing of the individual introns. On
the other hand, bimolecular exon ligation may occur naturally in
certain situations (32–35), perhaps as a way of joining alternative
exons encoded by different genes or by different transcripts from
the same gene. Such juxtaposition of exons in trans would be a
diffusion-limited process, which may be facilitated by the specific
interactions between the ESEs and appropriate SR proteins.
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